This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

Acute Psychological Sleep Stabilization in patients receiving inpatient treatment for depression

Acute psychological sleep stabilization in patients hospitalised with depression

Acute Psychological Sleep Stabilization, a brief, four-session CBT-I-based intervention adapted for inpatient psychiatric wards, was found to be feasible and acceptable among inpatients with depression, with preliminary evidence of reductions in insomnia and depressive symptoms.

Cognitive Behavioral Therapy for Insomnia (CBT-I), the first-line treatment for insomnia, is rarely implemented in inpatient psychiatric wards because of organizational constraints and short hospital stays. This study aimed to evaluate the feasibility and acceptability of Acute Psychological Sleep Stabilization (APS), a brief intervention adapted to this setting, and to estimate preliminary effects to inform future studies. Twenty inpatients with depressive symptoms and co-occurring sleep problems received four sessions of APS; the feasibility criterion was predefined as a dropout rate below 50% within 14 days of enrollment, and acceptability was measured using the Treatment Credibility Scale. Secondary outcome measures were insomnia severity (Insomnia Severity Index; ISI), depressive symptoms (Patient Health Questionnaire-9; PHQ-9), sleep variables derived from sleep diaries and actigraphy, and length of hospital stay. The feasibility criterion was met, with a dropout rate of 10% (2 of 20 participants), and acceptability ratings were high. The mean ISI score decreased from 20.1 to 13.6 (within-group effect size g = 0.97), and the mean PHQ-9 score decreased from 19.4 to 12.1; median sleep efficiency on day 7 was 87.7%, and the mean time to discharge was 22.7 days. The findings suggest that APS is feasible and highly acceptable among acutely ill inpatients with depression, is associated with clinically meaningful reductions in insomnia and depressive symptoms, and warrants evaluation in a larger randomized controlled trial (RCT).

All WCP 2026 summaries